Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NYSE:NVO
- CUSIP: N/A
- Web: www.novonordisk.com
- Market Cap: $104.02 billion
- Outstanding Shares: 2,495,800,000
- 50 Day Moving Avg: $38.81
- 200 Day Moving Avg: $35.72
- 52 Week Range: $30.89 - $57.44
Sales & Book Value:
- Trailing P/E Ratio: 18.57
- Foreward P/E Ratio: 16.67
- P/E Growth: 1.95
- Annual Revenue: $16.57 billion
- Price / Sales: 6.28
- Book Value: $2.37 per share
- Price / Book: 17.59
- Annual Dividend: $1.03
- Dividend Yield: 2.7%
- EBIDTA: $7.73 billion
- Net Margins: 33.97%
- Return on Equity: 90.61%
- Return on Assets: 42.44%
- Current Ratio: 1.26%
- Quick Ratio: 0.96%
- Average Volume: 2.31 million shs.
- Beta: 0.83
- Short Ratio: 0.69
Frequently Asked Questions for Novo Nordisk A/S (NYSE:NVO)
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared an annual dividend on Tuesday, February 7th. Investors of record on Monday, March 27th will be paid a dividend of $0.6634 per share on Tuesday, April 4th. This represents a yield of 1.99%. The ex-dividend date is Thursday, March 23rd. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S announced that its Board of Directors has authorized a share buyback program on Thursday, April 6th 2017, which authorizes the company to repurchase shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 18.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Friday, April, 29th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.53 by $0.02. The company earned $4.02 billion during the quarter, compared to the consensus estimate of $4.07 billion. Novo Nordisk A/S had a net margin of 33.97% and a return on equity of 90.61%. View Novo Nordisk A/S's Earnings History.
Where is Novo Nordisk A/S's stock going? Where will Novo Nordisk A/S's stock price be in 2017?
14 brokers have issued 1-year price objectives for Novo Nordisk A/S's stock. Their predictions range from $57.00 to $57.00. On average, they anticipate Novo Nordisk A/S's share price to reach $57.00 in the next twelve months. View Analyst Ratings for Novo Nordisk A/S.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Teva Pharmaceutical Industries Ltd (TEVA), Dr.Reddy's Laboratories Ltd (RDY), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), Endo International plc - (ENDP), Amarin Co. plc (AMRN), Synergy Pharmaceuticals (SGYP), Amphastar Pharmaceuticals (AMPH), Depomed (DEPO), SciClone Pharmaceuticals (SCLN), Sucampo Pharmaceuticals (SCMP), DURECT (DRRX), Summit Therapeutics PLC (SMMT), Merus Labs International (MSLI), Cardiome Pharma Corp (CRME), Cumberland Pharmaceuticals (CPIX), Albireo Pharma (ALBO) and Aralez Pharmaceuticals (ARLZ).
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Goran A. Ando M.D., Chairman of the Board
- Lars Fruergaard Joergensen, President, Chief Executive Officer
- Jeppe Christiansen, Vice Chairman of the Board
- Jesper Brandgaard, Chief Financial Officer, Executive Vice President
- Maziar Mike Doustdar, Executive Vice President, International Operations
- Mads Krogsgaard Thomsen, Chief Science Officer, Executive Vice President
- Henrik Ehlers Wulff, Executive Vice President, Product Supply
- Doug Langa, Senior Vice President, Head of North America Operations, President of Novo Nordisk Inc.
- Liselotte Hyveled, Director, Employee Representative
- Kasim Kutay, Director
Who owns Novo Nordisk A/S stock?
Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Loomis Sayles & Co. L P (0.76%), Renaissance Technologies LLC (0.66%), Bank of America Corp DE (0.48%), Fisher Asset Management LLC (0.41%), Folketrygdfondet (0.24%) and State Street Corp (0.22%). View Institutional Ownership Trends for Novo Nordisk A/S.
Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?
Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., JPMorgan Chase & Co., FMR LLC, Capital Fund Management S.A., Fayez Sarofim & Co, Fisher Asset Management LLC, Stock Yards Bank & Trust Co. and Atwood & Palmer Inc.. View Insider Buying and Selling for Novo Nordisk A/S.
Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?
Novo Nordisk A/S's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Karp Capital Management Corp, Sustainable Growth Advisers LP, River Road Asset Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Bank of America Corp DE. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy Novo Nordisk A/S stock?
Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Novo Nordisk A/S stock can currently be purchased for approximately $41.68.
Earnings History for Novo Nordisk A/S (NYSE:NVO)Earnings History by Quarter for Novo Nordisk A/S (NYSE NVO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/29/2016||Q1||$0.53||$0.55||$4.07 billion||$4.02 billion||View||Listen|
|10/29/2015||Q3||$0.47||$0.49||$4.03 billion||$3.99 billion||View||N/A|
|4/30/2015||Q1||$0.39||$0.45||$25.13 billion||$25.20 billion||View||N/A|
|1/30/2015||Q4||$2.48||$0.38||$24.67 billion||$24.59 billion||View||N/A|
|8/7/2014||Q2||$2.60||$0.48||$21.86 billion||$21.63 billion||View||N/A|
|5/1/2014||Q1||$0.44||$0.45||$20.83 billion||$20.30 billion||View||N/A|
|10/31/2013||Q1||$12.11||$2.20||$21.04 billion||$20.51 billion||View||N/A|
|8/8/2013||Q1||$11.97||$12.45||$21.09 billion||$21.38 billion||View||N/A|
|5/1/2013||$10.67||$10.98||$19.73 billion||$19.98 billion||View||N/A|
|1/31/2013||$9.77||$10.53||$20.83 billion||$20.96 billion||View||N/A|
Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
2017 EPS Consensus Estimate: $2.12
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
|Most Recent Dividend:||4/4/2017|
|Dividend Growth:||31.50% (3 Year Average)|
|Payout Ratio:||46.19% (Trailing 12 Months of Earnings) |
45.58% (Based on This Year's Estimates)
41.20% (Based on Next Year's Estimates)
|Track Record:||20 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Novo Nordisk A/S (NYSE NVO)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership Percentage: 6.65%Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/18/2015||Richmond Partners Master Limit||Insider||Sell||24,900||$1.28||$31,876.98|
Headline Trends for Novo Nordisk A/S (NYSE:NVO)
Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
Novo Nordisk A/S (NVO) Chart for Tuesday, May, 30, 2017